Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 1 | 2016

LaunchTrends: Venclexta (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche/AbbVie’s venetoclax). LaunchTrends: Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. The report evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity of Venclexta.

Questions Answered:

What are the awareness of and familiarity with Venclexta among hematologist-oncologists?
What are the perceived clinical advantages and disadvantages of Venclexta compared with other marketed agents used for treating relapsed/refractory CLL?
To what extent is Venclexta currently being used by surveyed hematologist-oncologists? Where does Venclexta fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Venclexta?
What promotional messages are being employed by Roche/AbbVie?

Scope:

Market covered: United States.

Primary research: 74 hematologist-oncologists; qualitative interviews with 10 respondents.

Indication coverage: Relapsed/refractory CLL.

Contact sales account_box

Report

Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)

Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…

north_east

Report

Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)

This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…

north_east

Report

Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)

Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…

north_east

Report

Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)

No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…

north_east

Report

Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)

Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…

north_east

Product logins

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 1 | 2016

Related Market Assessment Reports

Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)

Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)

Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)

Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)

Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)

Follow us

Contact us